US20220110918A1 - Compositions and methods for treatment of skin-related diseases and promoting dermatological health - Google Patents

Compositions and methods for treatment of skin-related diseases and promoting dermatological health Download PDF

Info

Publication number
US20220110918A1
US20220110918A1 US17/499,565 US202117499565A US2022110918A1 US 20220110918 A1 US20220110918 A1 US 20220110918A1 US 202117499565 A US202117499565 A US 202117499565A US 2022110918 A1 US2022110918 A1 US 2022110918A1
Authority
US
United States
Prior art keywords
composition
blend
patient
seed extract
grape seed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/499,565
Inventor
Suzy Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Script Essentials LLC
Original Assignee
Script Essentials LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Script Essentials LLC filed Critical Script Essentials LLC
Priority to US17/499,565 priority Critical patent/US20220110918A1/en
Assigned to SCRIPT ESSENTIALS, LLC reassignment SCRIPT ESSENTIALS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: COHEN, SUZY
Publication of US20220110918A1 publication Critical patent/US20220110918A1/en
Priority to US18/217,743 priority patent/US20230346751A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/446—Superoxide dismutase (1.15)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)

Definitions

  • composition of a preferred embodiment is substantially free of the following common allergens: gluten, wheat, eggs, peanuts, tree nuts, dairy, sugar and fish/shellfish.
  • the composition preferably does not contain artificial colors, flavors, or preservatives, and is free from magnesium stearate (a common lubricant used in the manufacture of pharmaceuticals and dietary supplements).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present disclosure relates to dietary supplements, for improving dermatological health. In embodiments, the composition is comprised of D-Biotin, grape seed extract, superoxide dismutase, zinc, Vitamin C, Lactobacillus Plantarum, Lactobacillus Reuteri, Lactobacillus Rhamnosus, or combinations/sub-combinations thereof.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • The present application claims priority and the benefit under 35 U. S.C. §119(e) to U.S. Provisional Patent Application Ser. No. 63/089,845 filed on Oct. 9, 2020, which is incorporated herein by reference in its entirety.
    • FIELD OF THE INVENTION
  • The present invention is directed to compounds for improving dermatological health. The present invention is also directed to methods for treatment of a disease or condition affecting the skin, as well as methods for formulating and administering a composition to address the same.
    • BACKGROUND OF THE INVENTION
  • The number of individuals suffering from or actively receiving treatment for skin-related disease has grown tremendously in the past 10 years. For example, recent studies have shown that approximately 85 million Americans are seen by a physician each year for treatment of skin disease. The estimated health care cost resulting from the same exceeds $75 billion. Presently, there are no fewer than 24 categories of skin disease recognized by the American Academy of Dermatology, including but not limited to acne, eczema, psoriasis, rosacea, ichthyosis, vitiligo, hives and dermatitis. With increasing cases of skin cancer and an aging population, the mortality rate is approximately 50%.
  • Accordingly, there is a long-felt but unresolved need to provide methods of treatment to address these and other problems related to skin-disease, which are the subject of the present disclosure.
    • SUMMARY OF THE INVENTION
  • The invention in embodiments relates to a compound, particularly in the form of a dietary supplement, which addresses skin-related disease and overcomes the shortcomings in the art with respect to improved skin health. As disclosed in more detail in the Detailed Description, the present invention provides compositions and methods for treating a person with unhealthy or diseased skin. Methods for forming the compound described herein are also disclosed.
  • Through experimentation it has been found that including various nutrients can be beneficial to people who have unhealthy skin or adverse dermatological conditions. In embodiments, a unique combination of the composition described herein is preferably administered orally in the form of a capsule, tablet, powder or lozenge. The unique combination has synergistic advantages over previously known compositions, all proportioned to provide the most benefit to people affected by the problems described above.
  • The composition is preferably comprised of a unique and novel formulation in pre-determined amounts, and further provides benefits previously unexpected. In a preferred embodiment, the composition is comprised of D-Biotin, grape seed extract (Preferably French grape seed extract), superoxide dismutase (preferably from melon), zinc, Vitamin C, Lactobacillus Plantarum, Lactobacillus Reuteri, Lactobacillus Rhamnosus, or combinations/sub-combinations thereof.
  • In another preferred embodiment, the composition comprises the following, with variability in dosages listed below:
  • 1) D-Biotin—between about 1,000 mcg and about 3,000 mcg;
  • 2) A proprietary blend—between about 50 mg and about 300 mg—of the following:
      • a) grape seed extract (preferably French grape seed extract);
      • b) superoxide dismutase (preferably derived from melon);
      • c) Zinc; and
      • d) Vitamin C;
  • 3) A proprietary blend—between about 1 Billion CFU/g and about 5 Billion CFU/g—of the following:
      • a) Lactobacillus Plantarum;
      • b) Lactobacillus Reuteri; and
      • c) Lactobacillus Rhamnosus;
  • In a most preferred embodiment, the composition comprises the following with dosages listed below:
  • 1) D-Biotin—about 2,000 mcg; 2) A proprietary blend—about 150 mg—of the following:
      • a) grape seed extract (preferably French grape seed extract);
      • b) superoxide dismutase (preferably derived from melon);
      • c) Zinc; and
      • d) Vitamin C;
  • 3) A proprietary blend—about 3 Billion CFU/g—of the following:
      • a) Lactobacillus Plantarum;
      • b) Lactobacillus Reuteri; and
      • c) Lactobacillus Rhamnosus
  • In one embodiment, the composition is provided as a dietary supplement. In one embodiment, the composition is administered in the form of a vegetable-based capsule, and two capsules are administered daily. In another embodiment, the composition is administered in the form of a powder, a gummy chew, a tablet, a lozenge or a liquid extract. In a preferred embodiment, the formulation is unflavored, but in further embodiments, the composition may contain one or more palatability agents to favorably alter the taste of the composition for human consumption.
  • Methods for treatment of individuals with skin-related disease or impairment, including but not limited to any of the disorders listed above, are also an express part of this disclosure. Methods for formulating and administering the supplement described herein are also within the scope of the present disclosure.
  • It is to be expressly understood that he above-described embodiments, objectives, and configurations are neither complete nor exhaustive. The Summary of the Invention is neither intended, nor should it be construed as being representative of the full extent and scope of the present invention. Other advantages will be apparent from the disclosure of the invention(s) contained herein.
  • Embodiments of the present invention are set forth in various levels of detail in the Summary of the Invention, and no limitation as to the scope of the present invention is intended by either the inclusion or non-inclusion of elements in this Summary of the Invention. Additional aspects of the present invention will be readily apparent from the view of one of ordinary skill in the art.
    • DETAILED DESCRIPTION
  • Although the following text sets forth a Detailed Description of numerous different embodiments, it should be understood that the legal scope of the description is defined by the words of the claims set forth at the end of this disclosure. The Detailed Description is to be construed as exemplary only, and does not describe every possible embodiment since describing every possible embodiment would be impractical, if not impossible. Numerous alternative embodiments could be implemented, using either current technology or technology developed after the filing date of this patent, which would be encompassed by the scope of the claims.
  • As used herein, references to “the present invention” or aspects thereof should be understood to mean certain embodiments of the present invention and should not necessarily be construed as limiting all embodiments to a particular description.
  • As used herein, the phrases “at least one”, “one or more”, and “and/or” are open-ended expressions that are both conjunctive and disjunctive in operation. For example, each of the expressions “at least one of A, B and C”, “at least one of A, B, or C”, “one or more of A, B, and C”, “one or more of A, B, or C” and “A, B, and/or C” means A alone, B alone, C alone, A and B together, A and C together, B and C together, or A, B and C together.
  • Unless otherwise indicated, all numbers expressing quantities, amounts, dimensions, conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about”.
  • The term “a” or “an” entity, as used herein, refers to one or more of that entity. As such, the terms “a” (or “an”), “one or more” and “at least one” can be used interchangeably herein.
  • The use of “including,” “comprising,” or “having” and variations thereof herein is meant to encompass the items listed thereafter and equivalents thereof as well as additional items. Accordingly, the terms “including,” “comprising,” or “having” and variations thereof can be used interchangeably herein.
  • It shall be understood that the term “means” as used herein shall be given its broadest possible interpretation in accordance with 35 U.S.C. Section 112(f). Accordingly, a claim incorporating the term “means” shall cover all structures, materials, or acts set forth herein, and all of the equivalents thereof. Further, the structures, materials, or acts and the equivalents thereof shall include all those described in the summary of the invention, brief description of the drawings, detailed description, abstract, and claims themselves.
  • In varying embodiments described herein, the present invention relates to a compound that improves an individual's skin and/or treats skin-related diseases. Certain elements of the novel compounds and methods for formulating the same are described in varying levels of detail herein.
  • Composition:
  • In embodiments, the composition is comprised of the foregoing elements:
  • 1) D-Biotin;
  • 2) A first proprietary blend comprising:
      • a) grape seed extract (preferably French grape seed extract);
      • b) superoxide dismutase (preferably derived from melon);
      • c) Zinc; and
      • d) Vitamin C;
  • 3) A second proprietary blend comprising:
      • a) Lactobacillus Plantarum;
      • b) Lactobacillus Reuteri; and
      • c) Lactobacillus Rhamnosus
  • Certain of these components are described in greater detail below.
  • D-Biotin
  • D-biotin has an important role in overall health of an individual. D-Biotin been shown to help the body convert food into energy. In addition, it can boost hair and nails and helps manage blood sugar levels, among other benefits. D-Biotin has also been shown to have a positive impact if taken during pregnancy.
  • In a preferred embodiment, the compound is comprised of a pre-determined amount of D-Biotin. In a most preferred embodiment, the compound is comprised of about 2,000 mcg of D-Biotin.
  • Vitamin C
  • Vitamin C, also known as ascorbic acid, is a water-soluble vitamin. In a most preferred embodiment, the compound is comprised of a pre-determined amount of vitamin C.
  • Vitamin C is a cofactor in at least eight enzymatic reactions, which through experimentation have been found to support healthy skin and provide anti-aging properties. These enzymatic reactions are important, and increasing evidence indicates vitamin C improves the absorption of minerals, most notably iron, in adults and children.
  • Furthermore, vitamin C is essential to wound healing and in the creation of skin, tendons, ligaments, and blood vessels and other regions of the human anatomy.
  • In a preferred embodiment, the composition comprises a first proprietary blend that is comprised of Vitamin C.
  • Zinc
  • In a preferred embodiment, the composition comprises a first proprietary blend that is comprised of Zinc. In a preferred embodiment, the Zinc is provided as Zinc Glycinate.
  • Absent Elements
  • In addition, the composition of a preferred embodiment is substantially free of the following common allergens: gluten, wheat, eggs, peanuts, tree nuts, dairy, sugar and fish/shellfish. The composition preferably does not contain artificial colors, flavors, or preservatives, and is free from magnesium stearate (a common lubricant used in the manufacture of pharmaceuticals and dietary supplements).
  • Additional Elements
  • In varying embodiments, the composition can further comprise variances, particularly with respect to encapsulation and/or powder formulations. The composition may be provided in the form of a capsule, and may made with Hypromellose (HPMC), Nu-RICE® and/or Nu-FLOW® ingredients.
  • According to certain embodiments, the compositions described herein can further be provided with one or more palatability agents. These palatability agents serve to add flavor to the composition so that an effective dosage is easier to be ingested. It is within the scope of the present invention that any safe, flavor enhancing palatability agent can be used in a composition of the present invention. Particularly suitable palatability agents for use in the composition of the present invention include, but are not limited to, plant oils, plant hydrolysates, yeast, yeast hydrolysates, and combinations thereof.
  • Methods
  • An aspect of the invention is a method to treat a patient experiencing skin disease, skin cancer, acne, eczema, psoriasis, rosacea, ichthyosis, vitiligo, hives, dermatitis, and seborrheic dermatitis, among other conditions, with a composition comprising a unique combination and blend of D-Biotin, grape seed extract (Preferably French grape seed extract), superoxide dismutase (preferably from melon), zinc, Vitamin C, Lactobacillus Plantarum, Lactobacillus Reuteri, Lactobacillus Rhamnosus, or combinations/sub-combinations thereof.
  • According to one embodiment, during the method the patient is treated by providing an effective amount of the composition. In certain embodiments, the composition can be taken by the patient daily, with no regard to meals or time of day ingested. In one such embodiment, the composition is administered daily to a patient in need thereof in the form of two capsules that are fit for human consumption.
  • According to another embodiment, a method to prepare a compound is disclosed. The components are mixed in a proprietary blend and may be provided in a delivery device, for example, in the form of a capsule, tablet, lozenge or powder.
  • While various embodiments of the present disclosure have been described in detail, it is apparent that modifications and alterations of those embodiments will occur to those skilled in the art. However, it is to be expressly understood that such modifications and alterations are within the scope and spirit of the present disclosure, as set forth in the following claims. Ranges have been discussed and used within the forgoing description. One of skill in the art will understand that any sub-range within the stated range would be suitable, as would any number within the broad range, without deviating from the spirit of the present invention.
  • The foregoing discussion of the disclosure has been presented for purposes of illustration and description. The foregoing is not intended to limit the disclosure to the form or forms disclosed herein. In the foregoing Detailed Description for example, various features of the disclosure are grouped together in one or more embodiments for the purpose of streamlining the disclosure. This method of disclosure is not to be interpreted as reflecting an intention that the claimed disclosure requires more features than are expressly recited in each claim. Rather, as the following claims reflect, inventive aspects lie in less than all features of a single foregoing disclosed embodiment.

Claims (19)

What is claimed is:
1. A method for treating a skin-related condition by administering an effective amount of a composition to a patient, wherein the composition comprises:
between about 1,000 mcg and about 3,000 mcg of D-Biotin;
between about 50 mg and about 300 mg of a first blend, comprising:
grape seed extract;
superoxide dismutase;
Zinc; and
Vitamin C;
between 1 Billion CFU/g and 5 Billion CFU/g of a second blend, comprising:
Lactobacillus Plantarum;
Lactobacillus Reuteri; and
Lactobacillus Rhamnosus.
2. The method of claim 1, wherein the composition is administered orally in the form of a capsule.
3. The method of claim 1, wherein the first blend of grape seed extract, superoxide dismutase, Zinc and Vitamin C comprises about 150 mg of the composition administered to the patient.
4. The method of claim 1, wherein the grape seed extract in the first blend is a French grape seed extract.
5. The method of claim 1, wherein the superoxide dismutase in the first blend if derived from melon.
6. The method of claim 1, wherein the second blend of Lactobacillus Plantarum, Lactobacillus Reuteri and Lactobacillus Rhamnosus comprises about 3 Billion CFU/g of the composition administered to the patient.
7. The method of claim 1, wherein the D-Biotin comprises about 2,000 mcg of the composition administered to the patient.
8. The method of claim 1, wherein the composition administered to the patient does not comprise additives selected from the group consisting of gluten, wheat, egg, peanuts, tree nuts, dairy, sugar, com, soy, artificial colors, preservatives, fish and shellfish.
9. The method of claim 1, wherein the composition administered to the patient further comprises at least one palatability agent.
10. The method of claim 9, wherein the palatability agent is selected from the group consisting of plant oils, plant hydrolysates, yeast, and yeast hydrolysates.
11. A method for treating a skin-related disease, comprising:
administering an effective amount of a composition to a patient, wherein the composition comprises:
about 2,000 mcg of D-Biotin;
about 150 mg of a first blend, wherein the first blend comprises:
grape seed extract;
superoxide dismutase;
Zinc; and
Vitamin C;
about 3 Billion CFU/g of a second blend, wherein the second blend comprises:
Lactobacillus Plantarum;
Lactobacillus Reuteri; and
Lactobacillus Rhamnosus.
12. The method of claim 11, wherein the composition is administered orally in the form of a capsule, tablet, lozenge or powder.
13. The method of claim 11, wherein the grape seed extract in the first blend is a French grape seed extract.
14. The method of claim 11, wherein the superoxide dismutase in the first blend if derived from melon.
15. The method of claim 11, wherein the composition administered to the patient does not comprise additives selected from the group consisting of gluten, wheat, egg, peanuts, tree nuts, dairy, sugar, com, soy, artificial colors, preservatives, fish and shellfish.
16. The method of claim 11, wherein the composition administered to the patient further comprises at least one palatability agent.
17. The method of claim 16, wherein the palatability agent is selected from the group consisting of plant oils, plant hydrolysates, yeast, and yeast hydrolysates.
18. The method of claim 11, wherein the composition is administered orally to the patient between 1-4 times each day.
19. The method of claim 11, wherein the skin-related disease is selected from the group consisting of skin cancer, acne, eczema, psoriasis, rosacea, ichthyosis, vitiligo, hives, dermatitis, and seborrheic dermatitis.
US17/499,565 2020-10-09 2021-10-12 Compositions and methods for treatment of skin-related diseases and promoting dermatological health Abandoned US20220110918A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17/499,565 US20220110918A1 (en) 2020-10-09 2021-10-12 Compositions and methods for treatment of skin-related diseases and promoting dermatological health
US18/217,743 US20230346751A1 (en) 2020-10-09 2023-07-03 Compositions and methods for treatment of skin-related diseases and promoting dermatological health

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063089845P 2020-10-09 2020-10-09
US17/499,565 US20220110918A1 (en) 2020-10-09 2021-10-12 Compositions and methods for treatment of skin-related diseases and promoting dermatological health

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/217,743 Continuation US20230346751A1 (en) 2020-10-09 2023-07-03 Compositions and methods for treatment of skin-related diseases and promoting dermatological health

Publications (1)

Publication Number Publication Date
US20220110918A1 true US20220110918A1 (en) 2022-04-14

Family

ID=81079439

Family Applications (2)

Application Number Title Priority Date Filing Date
US17/499,565 Abandoned US20220110918A1 (en) 2020-10-09 2021-10-12 Compositions and methods for treatment of skin-related diseases and promoting dermatological health
US18/217,743 Pending US20230346751A1 (en) 2020-10-09 2023-07-03 Compositions and methods for treatment of skin-related diseases and promoting dermatological health

Family Applications After (1)

Application Number Title Priority Date Filing Date
US18/217,743 Pending US20230346751A1 (en) 2020-10-09 2023-07-03 Compositions and methods for treatment of skin-related diseases and promoting dermatological health

Country Status (1)

Country Link
US (2) US20220110918A1 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010013179A1 (en) * 2008-07-29 2010-02-04 L'oreal Cosmetic use of microorganisms for the treatment of oily skin
WO2016149687A1 (en) * 2015-03-18 2016-09-22 Whole Biome, Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010013179A1 (en) * 2008-07-29 2010-02-04 L'oreal Cosmetic use of microorganisms for the treatment of oily skin
WO2016149687A1 (en) * 2015-03-18 2016-09-22 Whole Biome, Inc. Methods and compositions relating to microbial treatment and diagnosis of skin disorders

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Ahmed jan N, Masood S. Vitiligo. [Updated 2022 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559149/?report=classic (Year: 2022) *
Clatici, V. G., Racoceanu, D., Dalle, C., Voicu, C., Tomas-Aragones, L., Marron, S. E., & Wollina, U. (2017). Perceived age and life style. The specific contributions of seven factors involved in health and beauty. Maedica, 12(3), 191. (Year: 2017) *
Crane, M. French Grape and Melon Formula Improves Skin Radiance? Nutritional Outlook. September 20, 2016. (Year: 2016) *
Dumoulin M, Gaudout D, Lemaire B. Clinical effects of an oral supplement rich in antioxidants on skin radiance in women. Clin Cosmet Investig Dermatol. 2016;9:315-324 (Year: 2016) *
EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 2014. Scientific Opinion on the evaluation of allergenic foods and food ingredients for labelling purposes. EFSA Journal 2014;xx(xx):NNNN, 277 pp. doi:10.2903/j.efsa.2014.NNNN (Year: 2014) *
Hannuksela M, Haahtela T. Hypersensitivity reactions to food additives. Allergy. 1987 Nov;42(8):561-75. doi: 10.1111/j.1398-9995.1987.tb00386.x. PMID: 3322083. (Year: 1987) *
Katta R, Schlichte M. Diet and dermatitis: food triggers. J Clin Aesthet Dermatol. 2014 Mar;7(3):30-6. PMID: 24688624; PMCID: PMC3970830. (Year: 2014) *
Liuting Zeng, Ganpeng Yu, Yang Wu, Wensa Hao, Hua Chen, "The Effectiveness and Safety of Probiotic Supplements for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Preclinical Trials", Journal of Immunology Research, vol. 2021, Article ID 7552546, 14 pages, 2021. (Year: 2021) *
Saladi RN, Persaud AN. The causes of skin cancer: a comprehensive review. Drugs Today (Barc). 2005 Jan;41(1):37-53. doi: 10.1358/dot.2005.41.1.875777. PMID: 15753968. (Year: 2005) *
Tana Hintz, Karl K. Matthews, Rong Di, "The Use of Plant Antimicrobial Compounds for Food Preservation", BioMed Research International, vol. 2015, Article ID 246264, 12 pages, 2015. https://doi.org/10.1155/2015/246264 (Year: 2015) *

Also Published As

Publication number Publication date
US20230346751A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
DE102008036954B4 (en) Use of an amino sugar-containing composition
Vala et al. Medicinal benefits of coconut oil
US20120141611A1 (en) Methods and compositions using ergothioneine to treat a variety of health related factors
TW200843726A (en) Agent for relief or prevention of xerostomia
JP2016088933A (en) Age production inhibitor and application thereof
EP2456450A1 (en) Stevia extract or steviol for hair care
CN111202164B (en) Pet insect-repellent composite soft capsule and preparation method thereof
JP2012171901A (en) Food for oral-intake for hair growth of men
US20190134165A1 (en) Compositions and methods for treating thyroid disease
CN110099691A (en) Maca composition and application method
DE20220180U1 (en) Multivitamin food supplement including minerals, trace elements, fatty acids and natural materials has high vital ingredients content while showing minimal calorific loading
JP2009013083A (en) Orally administerable composition
KR101835799B1 (en) A cosmetic composition for manufacturing by the using of propolis, and the cosmetic manufactured by the composition
EP3290041A1 (en) Oral care composition
US20220110918A1 (en) Compositions and methods for treatment of skin-related diseases and promoting dermatological health
US20210315954A1 (en) Composition for increasing sexual desire or pleasure
CN116077474A (en) Methods and compositions for increasing energy expenditure using cinnamaldehyde
JP5004446B2 (en) Skin improver
EP2465517A1 (en) Composition based on extra virgin olive oils
US20210267911A1 (en) Compositions and methods for addressing vision impairment
JP2017132747A (en) Age production inhibitor
US11273191B2 (en) Administering compositions for improved immune system functioning
JP7421184B2 (en) Agents for increasing and/or maintaining skin moisture content and skin oil content
JP2000119126A (en) Effective composition for vital environment
WO2023182529A1 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: SCRIPT ESSENTIALS, LLC, COLORADO

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:COHEN, SUZY;REEL/FRAME:059002/0735

Effective date: 20220203

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION